1.Research progress on the mechanism of traditional Chinese medicine intervening in osteoarthritis by modulating the inflammatory microenvironment
Zuo WANG ; Yuxin LIU ; Yuxin QIAO ; Zhengyu YANG ; Ru WANG ; Wenbin LIAO ; Yan GAO ; Jiayi FENG ; Guohua LI
China Pharmacy 2026;37(6):823-828
The inflammatory microenvironment is closely associated with the initiation and progression of osteoarthritis (OA), specifically manifesting as macrophage activation, dysregulation of inflammatory cytokines, and redox imbalance. Following an overview of the pathological characteristics of the OA inflammatory microenvironment, this paper reviews the research progress on the mechanism of traditional Chinese medicine (TCM) intervening in OA by modulating the inflammatory microenvironment. It has been found that TCM monomers/active ingredients (such as total alkaloids from Strychnos nux-vomica , quercetin, triptolide, etc.), herb pairs (e.g. Angelica pubescens - Gentiana macrophylla , Carthami Flos-Lycopodii Herba), and TCM formulas (such as Zhuanggu jianxi formula, Duhuo jisheng decoction and Rongjin niantong formula, etc.) can inhibit macrophage activation, reduce the release of proinflammatory cytokines and the generation of reactive oxygen species by inhibiting multiple signaling pathways, including nuclear factor-κB, Wnt/ β -catenin, and mitogen-activated protein kinase, thereby alleviating the articular inflammatory microenvironment, restoring local joint homeostasis, and slowing the progression of OA.
2.Expert consensus on the application of artificial intelligence in lung cancer screening, diagnosis, and treatment (2026 edition)
Wenzhao ZHONG ; Haibo WANG ; Yi HU ; Hao ZHANG ; Jigang DAI ; Junqiang FAN ; Guibin QIAO ; Fan YANG ; Jian HU ; Fengwei TAN ; Xuening YANG ; Qiang PU ; Zihao CHEN ; Hongxia TIAN ; Lunxu LIU ; Hecheng LI ; Xiaolong YAN ; Zongyang YU ; Zhenbin QIU ; Yihua SUN ; Jing HU ; Yuhang SHI ; Zhifei GUO ; Peng ZHANG ; Kezhong CHEN ; Shugeng GAO ; Yilong WU
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2026;33(06):848-856
With the continuous deepening of the concept of precision diagnosis and treatment for lung cancer, how to achieve higher efficiency and accuracy in the screening, diagnosis, and treatment pathways in clinical practice has become an important issue that urgently needs to be overcome. The current clinical difficulty lies in the fact that despite continuous advancements in imaging and molecular diagnostic technologies, there are still limitations in manual efficiency and subjective experience when it comes to massive data analysis and multi-scale feature extraction. Artificial intelligence (AI), especially algorithm systems based on deep learning, is an innovative technology capable of deeply empowering medical big data. This method utilizes algorithms such as convolutional neural networks, combined with radiomics, pathomics, and multi-modal data fusion analysis, demonstrating immense potential in early precise detection and benign-malignant differentiation of pulmonary nodules, digital pathological subtype recognition and non-invasive prediction of driver genes, precise 3D surgical planning and automatic delineation of radiotherapy target volumes, as well as dynamic risk warning during follow-up. This innovative technology provides a brand-new solution for realizing intelligent and individualized lung cancer diagnosis and treatment models. This consensus, based on the latest evidence from evidence-based medicine and combined with the development trends in the AI field and real-world clinical needs, was ultimately formed by gathering the consensus opinions of multidisciplinary experts in radiology, pathology, thoracic surgery, and other fields. The main content covers the application specifications of AI in the three core scenarios of lung cancer screening, diagnosis, and treatment, the technical standards for data collection and algorithm validation, as well as the ethical and regulatory challenges faced at the current stage. It aims to clarify the applicable boundaries of AI as a clinical auxiliary decision support tool, providing scientific guidance and standardized exploration directions for peers currently engaged in or planning to carry out AI-assisted clinical diagnosis, treatment, and translation of lung cancer.
3.The first record of Anopheles messeae (Diptera: Culicidae) parasitized by water mites in China
Xue-ru CHEN ; Wen-zhen YAO ; Yu-hao LI ; Gui-chang LI ; Tao MENG ; Qun-ling FENG ; Xin-hui LIU ; Li-hong QIAO ; Xiang-ting WU ; Xue-feng ZHANG ; Cheng-lin LI ; Xue-cheng DONG ; Da-wei WANG ; Xiao-yan SI ; Yu-hong GUO
Acta Parasitologica et Medica Entomologica Sinica 2026;33(1):53-57
Objective This study reports on the obligatory parasitism of water mites Arrenurus sp. on Anopheles messeae at the Manzhouli Port, Inner Mongolia, China. Methods Duing July 2024, a survey on the mosquito diversity was conducted at the Manzhouli Port. Captured mosquitoes and their ectoparasites were identified to species level. Results A total of 1840 adult mosquitoes were collected, representing species from three genera: Culex(Cx. modestus, Cx. pipiens pallens), Aedes(Ae. dorsalis, Ae. flavidorsalis, Ae. flavescens), and Anopheles (An. messeae). Among all the mosqutioes specimens,3 out of 150 captured An. messeae were found to carry ectoparasitic mites, with number of 2,4,27 mites separately. Morphological and molecular identification reached the same result as water mites(Hydrachnidiae, Hydracrina). COI gene sequence showed 94% similarity with the closest species Arrenurus truncatellus. Conlusions Literature review suggests water mites are host-specific parasitism of mosquito species and herein with the first record of Arrenurus sp. parasiting on An. Messeae in the most high-latitude region globally.
4.Pharmacoeconomic evaluation of brivaracetam versus perampanel as add-on therapy for drug-resistant focal epilepsy
Jiale QIAO ; Fanqi LIU ; Yuchen TANG ; Jie CHENG ; Yan SHI ; Jun QI ; Zhiqiang DONG
China Pharmacy 2026;37(18):2382-2388
OBJECTIVE To evaluate the cost-effectiveness of brivaracetam (BRV) versus perampanel (PER) as add-on therapy for drug-resistant focal epilepsy in adults from the perspective of the Chinese healthcare system.METHODS A Markov model was established to simulate the progression of drug-resistant focal epilepsy in adults, with a simulation cycle of 5 months, a time horizon of 44 years, and a discount rate of 4.5%. Clinical data required for the model were derived from the phase Ⅲ clinical trial of BRV and a post hoc analysis of PER; cost data and utility data were obtained from Yaozh and related literature. The willingness-to-pay (WTP) threshold was set at twice China’s 2025 per capita gross domestic product (GDP) [199 330 yuan per quality-adjusted life year (QALY)], and a cost-effectiveness analysis was adopted to compare the cost-effectiveness of the regimens. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to confirm the stability of the base-case analysis conclusions.RESULTS The incremental cost-effectiveness ratio (ICER) of BRV 50 mg/d as an add-on therapy versus PER 8 mg/d was 44 823.08 yuan/QALY, which was below the WTP threshold; the ICER of BRV 200 mg/d versus PER 12 mg/d was 238 783.00 yuan/QALY, which was above the WTP threshold. In the one-way sensitivity analysis, the direct medical cost of seizures ≥53 times/year and the health utility value of a seizure-free state per year had a relatively large impact on the two ICER results mentioned above, respectively. Probabilistic sensitivity analysis indicated that the above results were robust.CONCLUSIONS For the selection of add-on therapy for drug-resistant focal epilepsy in adults in China, when twice China’s per capita GDP is used as the WTP threshold, BRV 50 mg/d has a cost-effectiveness advantage over PER 8 mg/d, whereas BRV 200 mg/d not have a cost-effectiveness advantage over PER 12 mg/d.
5.Sini San Treats Liver Fibrosis by Regulating Polarization of Intrahepatic Kupffer Cells
Yanyu QU ; Qiao GENG ; Zhuxiu ZHOU ; Dongyang ZHENG ; Jianmin YAN ; Huan LIU ; Li CHEN ; Feng ZHANG ; Desong KONG
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(23):34-46
ObjectiveTo investigate the mechanism by which Sini San (SNS) treats liver fibrosis through regulating the polarization of intrahepatic Kupffer cells. MethodsSixty SPF-grade male Balb/c mice were randomized into blank control, model, silymarin (0.2 g·kg-1), and low-, medium-, and high-dose (2.93, 5.85, 11.70 g·kg-1, respectively) SNS groups. A mouse model of liver fibrosis was induced by intraperitoneal injection of CCl4. After 5 weeks of administration, the body mass, liver pathological changes [Hematoxylin and Eosin (HE), Masson, and Sirius red staining], serum biochemical indicators [alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT)], liver fibrosis markers [procollagen type Ⅲ (PCⅢ), laminin (LN), and hyaluronic acid (HA)], inflammatory cytokines [interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interleukin-10 (IL-10)], and fibrosis-related proteins [α-smooth muscle actin (α-SMA), collagen type Ⅰ (Col Ⅰ), and collagen type Ⅲ (Col Ⅲ)] were assessed. A co-culture system of THP-1 cells (M1 macrophages) and human hepatic stellate cells (LX-2) was established. The cell experiment was designed with blank control (LX-2 alone), model (LX-2 + M1 macrophages), and low-, medium-, and high-dose SNS (co-culture with 5%, 10%, or 20% SNS-containing serum, respectively) groups. Cell viability, inflammatory cytokines, and macrophage phenotype were examined. Human primary hepatic Kupffer cells were allocated into blank control, M1 (LPS 100 μg·L-1+IFN-γ 20 μg·L-1), M2 (IL-4 20 μg·L-1+IL-13 20 μg·L-1), M1+M2, M1+SNS (supplemented with 10% SNS-containing serum for 2 h after culture under M1 conditions for 24 h), M2+SNS (supplemented with 10% SNS-containing serum for 2 h after culture under M2 conditions for 24 h), and M1+M2+SNS groups (supplemented with 10% SNS-containing serum for 2 h after culture under M1+M2 conditions for 24 h), and the expression of nuclear factor-κB (NF-κB) p65 and signal transducer and activator of transcription 3 (STAT3) at protein and mRNA levels was determined. ResultsCompared with the blank group, the model group exhibited increased serum levels of ALT, AST, ALP, PCⅢ, LN, HA, IL-6, and TNF-α, upregulated protein and mRNA levels of α-SMA, Col Ⅰ, and Col Ⅲ in the liver tissue (P<0.05, P<0.01), and decreased IL-10 level and STAT3 mRNA level (P<0.05, P<0.01), accompanied by marked collagen deposition and inflammatory infiltration in the liver. Compared with the model group, all doses of Sini San reversed these alterations (P<0.05, P<0.01), with the high-dose group showing the most pronounced effects. Cell experiments demonstrated that, compared with the blank control group, the model group had elevated levels of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and upregulated protein and mRNA levels of M1 markers [cluster of differentiation 86 (CD86, inducible nitric oxide synthase (iNOS), and monocyte chemoattractant protein-1 (MCP-1)] (P<0.01), along with declined level of IL-10 and downregulated expression of M2 markers [(CD163, CD206, and arginase-1 (Arg-1)] (P<0.05,P<0.01). Compared with the model group, treatment with Sini San-containing serum at various concentrations lowered the levels of pro-inflammatory cytokines and expression of M1 markers (P<0.05, P<0.01), while increasing the IL-10 level and M2 marker expression (P<0.05, P<0.01). Additionally, Sini San downregulated the mRNA level of NF-κB and upregulated the mRNA level of STAT (P<0.05, P<0.01). In the experiment with human primary Kupffer cells, compared with the blank group, the M1 group showed increased NF-κB p65 expression (P<0.01) and decreased STAT3 expression (P<0.05), whereas the M2 group exhibited increased STAT3 expression (P<0.01). Compared with the respective model groups, Sini San-containing serum reversed the M1-induced overexpression of NF-κB p65 (P<0.05, P<0.01) and further enhanced the M2-induced STAT3 expression (P<0.05, P<0.01). ConclusionSini San can inhibit the NF-κB p65/STAT3 signaling pathway and repolarize intrahepatic Kupffer cells from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype to attenuate inflammation and suppress hepatic stellate cell activation and collagen deposition, thereby exerting anti-fibrotic effect.
6.Influencing factors for hand, foot, and mouth disease in Binzhou City based on a Bayesian spatio-temporal model
XU Xinying ; YAN Wei ; SHI Xinglong ; LÜ ; Jing ; YUE Fang ; QIAO Yingyi ; LIU Guanxiang ; LI Xiujun
Journal of Preventive Medicine 2026;38(2):161-165
Objective:
To investigate the epidemiological characteristics and influencing factors for hand, foot, and mouth disease (HFMD) incidence in Binzhou City, Shandong Province, so as to provide the evidence for developing HFMD prevention and control strategies.
Methods:
Data on HFMD cases in Binzhou City from 2017 to 2023 were collected through the Infectious Disease Reporting Information System of Chinese Disease Prevention and Control Information System. Meteorological data during the same period were collected from the fifth-generation European Centre for Medium-Range Weather Forecasts. The incidence of HFMD was calculated, and the temporal, population, and regional distribution characteristics of HFMD were analyzed descriptively. Bayesian spatiotemporal model was used to analyze the influencing factors for HFMD incidence
Results:
From 2017 to 2023, a total of 17 314 HFMD cases were reported in Binzhou City, with an annual average reported incidence of 62.57/105. The incidence peak was from June to September, and a secondary peak appeared from October to November in some years. The annual average reported incidences were higher in Bincheng District and Yangxin County, which were 107.41/105 and 72.95/105, respectively. There were 10 461 males and 6 853 females, with a male-to-female ratio of 1.53∶1. The age was mainly 1-3 years, with 11 713 cases accounting for 67.65%. Bayesian spatiotemporal model analysis showed that the risk of HFMD incidence had obvious seasonality and regionality. From 2017 to 2019 and in 2021, the peaks occurred in weeks 24-27 and 44-47 each year, with RR values of 1.771-6.747. From 2022 to 2023, it showed a single peak distribution. The RR values were all >1 in Bincheng District, Yangxin County, and Huimin County. Average temperature (RR=1.092, 95%CI: 1.080-1.105) and average relative humidity (RR=1.015, 95%CI: 1.008-1.022) were positively correlated with the risk of HFMD incidence, while average wind speed (RR=0.749, 95%CI: 0.655-0.856) was negatively correlated with the risk of HFMD incidence.
Conclusions
HFMD in Binzhou City mainly occurs in summer and in central areas. Males and children aged 1-3 years are high-risk populations. The risk of HFMD incidence increases with the increase of average temperature and average relative humidity, and decreases with the increase of average wind speed.
7.Palpitations, Shortness of Breath, Weakness in Limbs, Edema, and Dyspnea: A Rare Inflammatory Myopathy with Positive Aniti-mitochondrial Antibodies and Cardiac Involvement
Chunsu LIANG ; Xuchang ZHANG ; Ning ZHANG ; Lin KANG ; Xiaohong LIU ; Jiaqi YU ; Yingxian LIU ; Lin QIAO ; Yanli YANG ; Xiaoyi ZHAO ; Ruijie ZHAO ; Na NIU ; Xuelian YAN
Medical Journal of Peking Union Medical College Hospital 2025;16(1):248-255
This article presents a case study of a patient who visited the Geriatric Department of Peking Union Medical College Hospital due to "palpitations, shortness of breath for more than 2 years, limb weakness for 6 months, edema, and nocturnal dyspnea for 2 months". The patient exhibited decreased muscle strength in the limbs and involvement of swallowing and respiratory muscles, alongside complications of heart failure and various arrhythmias which were predominantly atrial. Laboratory tests revealed the presence of multiple autoantibodies and notably anti-mitochondrial antibodies. Following a comprehensive multidisciplinary evaluation, the patient was diagnosed with anti-mitochondrial antibody-associated inflammatory myopathy. Treatment involved a combination of glucocorticoids and immunosuppressants, along with resistance exercises for muscle strength and rehabilitation training for lung function, resulting in significant improvement of clinical symptoms. The case underscores the importance of collaborative multidisciplinary approaches in diagnosing and treating rare diseases in elderly patients, where careful consideration of clinical manifestations and subtle abnormal clinical data can lead to effective interventions.
8.Effects of different storage temperatures and durations on the activity of coagulation factor Ⅷ and Ⅸ in whole blood
Hehe WANG ; Tiantian WANG ; Jie WANG ; Cuicui QIAO ; Wei LIU ; Xueqin ZHANG ; Yan CHENG ; Yunhai FANG ; Xinsheng ZHANG
Chinese Journal of Blood Transfusion 2025;38(6):824-827
Objective: To investigate the effects of different storage temperatures and durations on the activities of coagulation factor Ⅷ (Factor Ⅷ, FⅧ) and coagulation factor Ⅸ (Factor Ⅸ, FⅨ) after whole blood collection, so as to provide data support for the optimal storage conditions. Methods: A total of 16 mL of whole blood was collected from each of the 20 healthy volunteers at our blood center and aliquoted into 8 sodium citrate anticoagulant tubes. Two tubes were immediately centrifuged for the measurement of FⅧ and FⅨ activity levels. The remaining 6 tubes of whole blood were respectively stored under room temperature and low-temperature conditions. At 2, 4, and 6 h, the whole blood samples were centrifuged and analyzed for FⅧ and FⅨ activity levels. The mean values of the two immediately tested tubes were used as the control group, while other tubes were designated as the experimental groups for comparison. Statistical analysis was performed using SPSS 26.0. Results: The activity of FⅧ in whole blood remained stable after 4 hours of storage at both room temperature and low temperature (116.53±25.95 vs 125.22±27.33, 109.77±23.23 vs 125.22±27.33) (P>0.05 for both). However, by 6 hours, FⅧ activity showed a statistically significant decline compared to the control group (108.65±22.92 vs 125.22±27.33, 100.46±20.19 vs 125.22±27.33) (P<0.05 for both), though the room temperature group results were closer to the control values. The activity of FⅨ in whole blood remained stable after 6 hours of storage under both conditions (97.14±19.48 vs 96.76±19.67, 97.10±17.45 vs 96.76±19.6) (P>0.05 for all comparisons). Conclusion: For whole blood samples after collection, storage at either room temperature or low temperature for up to 4 hours does not compromise the accuracy of test results. When stored for 6 hours, FⅨ activity remains stable, whereas FⅧ activity decreases significantly. Notably, FⅧ activity demonstrates better stability at room temperature than under low-temperature conditions within the 6-hour storage.
10.Mechanism of puerarin improving myocardial contractile function in myocardial hypertrophy by inhibiting ferroptosis via Nrf2/ARE/HO-1 signaling pathway.
Yan-Dong LIU ; Wei QIAO ; Zhao-Hui PEI ; Guo-Liang SONG ; Wei JIN ; Wei-Bing ZHONG ; Qin-Qin DENG
China Journal of Chinese Materia Medica 2025;50(16):4679-4689
This study aims to explore the specific mechanism by which puerarin inhibits ferroptosis and improves the myocardial contractile function in myocardial hypertrophy through the nuclear factor erythroid 2-related factor 2(Nrf2)/antioxidant response element(ARE)/heme oxygenase-1(HO-1) signaling pathway. The hypertrophic cardiomyocyte model was established using phenylephrine, and H9c2 cells were divided into control group, model group, puerarin group, and puerarin+ML385 group. Cell viability and surface area were detected by cell counting kit-8(CCK-8) and immunofluorescence experiments. The mitochondrial membrane potential and Ca~(2+) concentration were measured. The ferroptosis-related indicators were detected by biochemical and fluorescence staining methods. The expression of proteins related to ferroptosis and the Nrf2/ARE/HO-1 signaling pathway was detected by Western blot. A myocardial hypertrophy model was established, and 40 rats were randomly divided into sham group, model group, puerarin group, and puerarin+Nrf2 inhibitor(ML385) group, with 10 rats in each group. Echocardiogram, hemodynamic parameters, and myocardial hypertrophy parameters were measured. Histopathological changes of myocardial tissues were observed by hematoxylin and eosin(HE) staining and Masson staining. Biochemical methods, enzyme-linked immunosorbent assay(ELISA), and fluorescence staining were used to detect inflammatory factors and ferroptosis-related indicators. Immunohistochemistry was used to detect the expression of proteins related to ferroptosis and the Nrf2/ARE/HO-1 signaling pathway. Cell experiments showed that puerarin intervention significantly enhanced the viability of hypertrophic cardiomyocytes, reduced their surface area, and restored mitochondrial membrane potential and Ca~(2+) homeostasis. Mechanism studies revealed that puerarin promoted Nrf2 nuclear translocation, upregulated the expression of HO-1, solute carrier family 7 member 11(SLC7A11), and glutathione peroxidase 4(GPX4), and decreased malondialdehyde(MDA), reactive oxygen species(ROS), and iron levels. These protective effects were reversed by ML385. In animal experiments, puerarin improved cardiac function in rats with myocardial hypertrophy, alleviated myocardial hypertrophy and fibrosis, inhibited inflammatory responses and ferroptosis, and promoted nuclear Nrf2 translocation and HO-1 expression. However, combined intervention with ML385 led to deterioration of hemodynamics and a rebound in ferroptosis marker levels. In conclusion, puerarin may inhibit cardiomyocyte ferroptosis through the Nrf2/ARE/HO-1 signaling pathway, thereby improving myocardial contractile function in myocardial hypertrophy.
Animals
;
NF-E2-Related Factor 2/genetics*
;
Rats
;
Ferroptosis/drug effects*
;
Signal Transduction/drug effects*
;
Isoflavones/pharmacology*
;
Male
;
Rats, Sprague-Dawley
;
Cardiomegaly/genetics*
;
Myocytes, Cardiac/metabolism*
;
Antioxidant Response Elements/drug effects*
;
Myocardial Contraction/drug effects*
;
Heme Oxygenase-1/genetics*
;
Cell Line


Result Analysis
Print
Save
E-mail